# Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Source: https://onco.cc/key-papers/paper-esmo-pancreatic-cancer-guideline-ann-oncol-2023/  
OnCo record `paper-esmo-pancreatic-cancer-guideline-ann-oncol-2023` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The European oncology society's 2023 guideline for pancreatic cancer, covering diagnosis, staging, surgery, chemotherapy before and after surgery, treatment of advanced disease and follow-up; the reference standard European and UK care is compared against.

## Summary

ESMO Clinical Practice Guideline for pancreatic cancer, published in Annals of Oncology in 2023 by Conroy, Pfeiffer, Vilgrain, Lamarca, Seufferlein, O'Reilly, Hackert, Golan, Prager, Haustermans, Vogel and Ducreux for the ESMO Guidelines Committee. Europe PMC indexes no abstract for this article, so OnCo carries no figures from it; the guideline itself is open on the ESMO website. A 2024 letter from radiation oncologists (Huguet and colleagues) argued that radiotherapy for locally advanced disease had been given too little weight, and the authors replied in the same issue.

## Fields

- Kind: Key paper
- Last checked: 2026-09-24
- Tags: pancreatic-evidence
- Journal: Annals of Oncology
- Year: 2023
- DOI: 10.1016/j.annonc.2023.08.009
- Authors: Conroy T, Pfeiffer P, Vilgrain V, et al.
- Findings: No abstract is indexed on Europe PMC; recommendations are read from the guideline itself.
- What it means: This is the European standard the UK and NHS page for pancreatic cancer is compared against; NICE guideline NG85 (2018) covers the same ground with an older evidence base and a narrower set of funded drugs.
- Caveats: Published before the 2026 daraxonrasib result and approval, and before PREOPANC-2 and NORPACT-1 were in print.; Guideline text, not a trial; the strength of each recommendation is graded within the document.

## Sources

- Ann Oncol 2023: https://doi.org/10.1016/j.annonc.2023.08.009
- PubMed: https://pubmed.ncbi.nlm.nih.gov/37678671/
- ESMO guidelines: pancreatic cancer: https://www.esmo.org/guidelines/esmo-clinical-practice-guidelines-gastrointestinal-cancers
- NICE NG85: pancreatic cancer in adults, diagnosis and management (2018): https://www.nice.org.uk/guidance/ng85

## Connected records

- collections: [ESMO Clinical Practice Guidelines & MCBS](https://onco.cc/collections/esmo-guidelines/)
- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- institutions: [European Society for Medical Oncology (ESMO)](https://onco.cc/institutions/esmo/)
- trials: [NAPOLI 3](https://onco.cc/trials/napoli-3/), [POLO](https://onco.cc/trials/polo/), [PRODIGE 24 / CCTG PA6](https://onco.cc/trials/prodige-24/)
- people: [Eileen M. O'Reilly](https://onco.cc/people/eileen-oreilly/), [Talia Golan](https://onco.cc/people/talia-golan/), [Thierry Conroy](https://onco.cc/people/thierry-conroy/)
- journals: [Annals of Oncology](https://onco.cc/journals/annals-of-oncology/)
- roadmaps: [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/paper-esmo-pancreatic-cancer-guideline-ann-oncol-2023.json